Viridian Q3: Lumvoa Launch Hits $24.7M, Cash $955M, Elegrobart BLA Set for Q1 2027
VRDN has more than doubled off its 52-week low of $13.18 on elevated volume (2.2× avg).
Summary
Viridian's first Lumvoa quarter brought in $24.7 million with over 100 patients on therapy, and $955.2 million in cash is now expected to carry the company to profitability. The elegrobart BLA stays on track for Q1 2027.
Key Events · Earnings and Guidance · VRDN
-
Lumvoa Launch Beats Early Expectations
Q3 2026 net product revenue was $24.7 million with more than 100 patients on therapy at quarter end, the first commercial quarter for Lumvoa in thyroid eye disease.
-
Cash Runway Extended to Profitability
Cash, cash equivalents and marketable securities totaled $955.2 million as of September 30, 2026; management expects existing cash plus Lumvoa and potential elegrobart revenue to fund operations through profitability.
-
Launch Costs Widen Quarterly Loss
SG&A rose to $57.6 million from $24.3 million a year earlier on commercial build-out, and the net loss widened to $101.2 million from $34.6 million.
-
Elegrobart BLA on Track for Q1 2027
Viridian still expects to submit a BLA for subcutaneous elegrobart in TED in Q1 2027, launchable in an autoinjector with Q4W and Q8W dosing.
Analysis · VRDN · Life Sciences
The first commercial quarter is the whole story: Lumvoa generated $24.7 million in net product revenue with more than 100 patients on therapy, well ahead of a typical launch trajectory, and management called it above expectations. With $955.2 million in cash plus anticipated Lumvoa revenue, the company now projects funding through profitability, removing the financing overhang that has hung over the stock. The cost of that launch is visible too — SG&A jumped to $57.6 million from $24.3 million and the quarterly net loss widened to $101.2 million from $34.6 million — but with a permanent J-code effective January 1, 2027 and an elegrobart BLA on track for Q1 2027, the revenue ramp has a clear runway. Near-term milestones: VRDN-008 phase 1 data and VRDN-292 phase 1 initiation, both expected in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRDN was trading at $27.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $13.18 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.